Get the Stockscreener App
11.07
2.12%
-0.24
After Hours:
11.33
0.26
+2.35%
Fibrogen Inc stock is traded at $11.07, with a volume of 35,627.
It is down -2.12% in the last 24 hours and down -8.51% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$11.31
Open:
$11.28
24h Volume:
35,627
Relative Volume:
0.77
Market Cap:
$44.77M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-3.7782
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-9.63%
1M Performance:
-8.51%
6M Performance:
+62.14%
1Y Performance:
+29.25%
1-Day Range:
$11.02
$11.55
1-Week Range:
$11.02
$12.46
52-Week Range:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
11.07 | 47.43M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.28 | 103.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.24 | 62.05B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.58 | 59.25B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
797.35 | 48.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
341.62 | 37.84B | 4.56B | -176.77M | 225.30M | -1.7177 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
Live market analysis of FibroGen Inc.Buy Signal & Expert Approved Momentum Trade Ideas - newser.com
Real time scanner hits for FibroGen Inc. explained2025 Market Overview & Capital Efficiency Focused Strategies - newser.com
Reversal indicators forming on FibroGen Inc. stockInflation Watch & Fast Exit and Entry Strategy Plans - newser.com
Will FibroGen Inc. (1FG0) stock see valuation expansionJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
How FibroGen Inc. (1FG0) stock reacts to monetary easing2025 Valuation Update & AI Powered Market Trend Analysis - newser.com
Published on: 2025-10-03 05:46:29 - newser.com
What analysts say about FibroGen Inc stockMid Cap Growth Trends & Maximize ROI With Proven Growth Stocks - earlytimes.in
FibroGen Inc Stock Analysis and ForecastEquity Performance Review & High Return Portfolio Growth - earlytimes.in
What drives FibroGen Inc stock priceMonthly Performance Summary & Reap the Rewards of Patience + Planning - earlytimes.in
What analysts say about FibroGen Inc 1FG0 stockBollinger Bands Signals & Exceptional Capital Growth - earlytimes.in
FibroGen stock advances as H.C. Wainwright reiterates Buy rating on FG-3246 progress - Investing.com Nigeria
FibroGen stock advances as H.C. Wainwright reiterates Buy rating on FG-3246 progress By Investing.com - Investing.com South Africa
William Blair Remains a Hold on FibroGen (FGEN) - The Globe and Mail
H.C. Wainwright Maintains FibroGen(FGEN.US) With Buy Rating, Maintains Target Price $43 - 富途牛牛
FibroGen initiates phase 2 trial of FG-3246 for prostate cancer By Investing.com - Investing.com South Africa
FibroGen initiates phase 2 trial of FG-3246 for prostate cancer - Investing.com India
FGEN: HC Wainwright & Co. Reiterates 'Buy' Rating with $43 Targe - GuruFocus
FibroGen (FGEN) Launches Phase 2 Trial for Antibody-Drug Conjuga - GuruFocus
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - The Manila Times
FibroGen Initiates Phase 2 Trial for FG-3246 in Metastatic Castration-Resistant Prostate Cancer, Evaluating Companion PET Imaging Agent FG-3180 - Quiver Quantitative
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a - GlobeNewswire
First-in-Class CD46 Targeting ADC: FibroGen's FG-3246 Enters Phase 2 Trial for Advanced Prostate Cancer - Stock Titan
FibroGen Stock Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Treasury Yields: Is FibroGen Inc stock a buy or sell2025 Trade Ideas & Reliable Momentum Entry Alerts - خودرو بانک
Market Catalysts: Is FibroGen Inc vulnerable to short sellersVolume Spike & Free Safe Entry Trade Signal Reports - خودرو بانک
Fed Watch: Why is FibroGen Inc stock going upJuly 2025 Price Swings & Low Drawdown Trading Strategies - khodrobank.com
Aug Volume: Will FibroGen Inc stock benefit from M A2025 Historical Comparison & Capital Protection Trade Alerts - خودرو بانک
What moving averages say about FibroGen Inc.Options Play & High Accuracy Trade Signal Alerts - newser.com
What is FibroGen Incs revenue forecast2025 Trading Volume Trends & Weekly Watchlist of Top Performers - khodrobank.com
Volatility Watch: Can FibroGen Inc sustain its profitabilityWall Street Watch & Smart Allocation Stock Tips - khodrobank.com
Meme Stocks: Is FibroGen Inc stock a value trapBull Run & Breakout Confirmation Alerts - خودرو بانک
Wall Street Zen Upgrades FibroGen (NASDAQ:FGEN) to "Hold" - MarketBeat
Growth Value: Will FibroGen Inc benefit from rising consumer demandQuarterly Trade Review & Consistent Income Trade Recommendations - خودرو بانک
FibroGen appoints David DeLucia CFO - MSN
Aug Selloffs: Is FibroGen Inc. affected by consumer sentimentGap Up & Real-Time Volume Triggers - khodrobank.com
FibroGen Sells Subsidiary to AstraZeneca for $220M - MSN
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):